ArticleFrontiers in oncology2026
Acute promyelocytic leukemia with a novel TTMV::RARA fusion initially presenting as vertebral myeloid sarcoma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute promyelocytic leukemia (APL) caused by the TTMV::RARA fusion gene is extremely rare, with fewer than 10 formally reported cases worldwide, and routine molecular tests often fail to detect it. This case is unique because the disease first manifested as vertebral myeloid sarcoma. Although bone marrow morphology and immunophenotyping strongly suggested APL, routine diagnostic methods could not confirm the disease, and the final diagnosis relied on whole- transcriptome sequencing. Case summary: A 39- year- old man was admitted for persistent lower back pain and limited movement of the left lower limb. Imaging revealed destruction of the T9 vertebral body with paravertebral and mediastinal soft- tissue masses. Pathology of the resected mass confirmed myeloid sarcoma. The patient developed pancytopenia and coagulopathy. Bone marrow morphology and flow cytometry showed classic features of APL, and all- trans retinoic acid (ATRA) induction therapy was initiated. However, PML:: RARA PCR and RARa FISH were negative, fusion gene screening and karyotyping found no abnormalities, and the diagnosis was revised to AML, prompting a switch to IA chemotherapy. As the diagnosis remained unclear, whole- transcriptome sequencing was performed and revealed a TTMV::RARA fusion, which was confirmed by RT- PCR. The patient was ultimately diagnosed with TTMV::RARA APL. He later discontinued treatment and died months afterward. Conclusion: This report presents a rare adult case of TTMV::RARA acute promyelocytic leukemia presenting as vertebral myeloid sarcoma. Whole-transcriptome sequencing was essential for diagnosis after routine molecular tests were negative, highlighting the importance of considering rare RARA fusions in APL-like cases lacking PML::RARA. TTMV::RARA APL may be sensitive to ATRA/ATO-based therapy; however, the patient discontinued treatment. Further cases and clinical experience are needed to optimize management strategies for this rare APL subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.